학술논문

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Document Type
Article
Author
Orrell, C.Hagins, D.P.Belonosova, E.Porteiro, N.Walmsley, S.Falcó, V.Man, C.Y.Buchanan, A.M.Vavro, C.Smith, K.Y.Aylott, A.Wynne, B.Aboud, M.Cahn, P.E.Cassetti, L.I.Porteiro Barreira, N.Angel, J.B.de Pokomandy, A.Harris, M.Rachlis, A.R.Allavena, C.Bouchaud, O.Gatey, C.Rami, A.Casari, S.Di Perri, G.Lazzarin, A.Maggiolo, F.Penco, G.Quirino, T.Rizzardini, G.Andrade-Villanueva, J.-F.Sierra-Madero, J.G.Branco, T.Serrao, R.Teofilo, E.J.Melendez-Rivera, I.Santiago, L.Zorrilla, C.D.Chernova, O.E.Pokrovsky, V.Rakhmanova, A.G.Tsybakova, O.Voronin, E.Vally, T.Farisani, L.M.Sebopa, B.L.Barros, C.A.Cano Sánchez, A.Castaño, M.Falcó Ferrer, V.González García, J.J.Hernandez-Quero, J.Negredo Puigmal, E.Pérez Elías, M.J.Podzamczer Palter, D.Portilla, J.S.Viciana Fernández, P.Manosuthi, W.Ruxrungtham, K.Dockrell, D.H.Hay, P.E.Johnson, M.A.Mackie, N.E.Orkin, C.M.Taylor, S.Bhatti, L.Brar, I.Brennan, R.O.Cade, J.L.Casanas, B.Casey, K.Cunningham, D.DeJesus, E.Dietz, C.Dretler, R.H.Eron, J.J.Felizarta, F.A.B.Fife, K.H.Hoffman-Terry, M.Jain, M.Johnson, M.A.Kinder, C.A.Kumar, P.N.Lewis, S.T.McDonald, C.K.Meza, A.D.Mounzer, K.C.Newman, C.L.Osiyemi, O.O.Poblete, R.Presti, R.M.Ramgopal, M.Rosenstock, J.Samuel, R.Sandkovsky, U.S.Shon, A.S.Y.Skiest, D.J.Sloan, L.M.Small, C.B.Tebas, P.Van Dam, C.N.
Source
In: The Lancet HIV. (The Lancet HIV, 1 December 2017, 4(12):e536-e546)
Subject
Language
English
ISSN
23523018